Novel chlorin e6 derivatives, pharmaceutically acceptable salts thereof, as well as preparation methods and applications of novel chlorin e6 derivatives and pharmaceutically acceptable salts

Abstract

The invention relates to novel chlorin e6 derivatives, pharmaceutically acceptable salts thereof, as well as preparation methods and applications of the novel chlorin e6 derivatives and the pharmaceutically acceptable salts and belongs to the technical field of medicines. The chlorin e6 ether amino acid derivatives comprise compounds shown as the general structural formula I and optical isomers ofthe general structural formula I. The preparation method of the novel chlorin e6 derivatives comprises steps as follows: 3-vinyl in chlorin e6 is etherified, and 15-ethylcarboxyl and amino acid are subjected to peptides formation. The chlorin e6 ether amino acid derivatives and the pharmaceutically acceptable salts thereof can be taken as photodynamic antitumor drugs for application. Compared with an existing clinically applied similar photosensitizer talaporfin, the chlorin e6 ether amino acid derivatives have the advantages of being high in photodynamic antitumor activity, high in ratio ofdark toxicity to phototoxicity and the like and can be applied to preparation of new photodynamic antitumor drugs including photodynamic cancer treating drugs, photodynamic treatment drugs for benignvascular diseases such as senile macular degeneration and nevus flammeus as well as photodynamic treatment drugs for condyloma acuminate.

Description

technical field [0001] The present invention relates to the field of medical technology, in particular to a new class of chlorin photosensitizers - chlorin e6 ether amino acid derivatives and pharmaceutically acceptable salts thereof, their preparation methods and their use in the preparation of anti-tumor and other drugs in the application. Background technique [0002] Photodynamic therapy (PDT) is a new technology for tumor treatment developed in the early 1980s. The principle of treatment is to irradiate the lesion (tumor) tissue that takes in the photosensitizer with a specific wavelength of laser light, and the photosensitizer induces matrix oxygen (O 2 ) excited to produce singlet oxygen ( 1 o 2 ) and other reactive oxygen species (ROS), leading to apoptosis or necrosis of tumor cells and playing a role in tumor therapy. The so-called specific wavelength refers to the maximum absorption wavelength of the photosensitizer in the red light region (>600nm). Since ...

AI Technical Summary

Problems solved by technology

The first generation of porphyrin photosensitizers such as porfimer sodium (porfimer sodium) have been successfully used in the clinical treatment of tumors, and have achieved remarkable curative effect, but there are also obvious defects: 1) the maximum absorption wavelength in the red light region is short (630nm), making the wavelength The matching laser penetrates and kills the tumor deeply enough and the molar absorption coefficient (ε) is small, resulting in low photosensitivity; 2) It is a multi-component porphyrin mixture; 3) The slow clearance in the body leads to high residual phototoxicity, and the patient receives treatment It needs to be protected from light for 4 to 8 weeks afterwards, causing great psychological pain to the patient.

Nevertheless, there are still few types of drugs for the treatment of tumors, and the options for patients are limited, and the therapeutic effect also has great room for improvement, and its toxicity needs to be further reduced

Images